Evropska unija - slovenščina - EMA (European Medicines Agency)

vbi vaccines b.v. - površinski antigen hepatitisa b - hepatitis b - cepiva - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sanofi pasteur - davični toksoid; hemaglutinin, filamentozni; tetanusni toksoid; toksoid b. pertussis; pertaktin; fimbrij tipa 2 in 3 - suspenzija za injiciranje v napolnjeni injekcijski brizgi - davični toksoid 2 i.e. / 1 brizga  hemaglutinin, filamentozni5 i.e. / 1 brizga  tetanusni toksoid20 i.e. / 1 brizga  toksoid b. pertussis2,5 i.e. / 1 brizga  pertaktin3 i.e. / 1 brizga  fimbrij tipa 2 in 35 i.e. / 1 brizga; hemaglutinin, filamentozni 5 i.e. / 1 brizga  tetanusni toksoid20 i.e. / 1 brizga  toksoid b. pertussis2,5 i.e. / 1 brizga  pertaktin3 i.e. / 1 brizga  fimbrij tipa 2 in 35 i.e. / 1 brizga; tetanusni toksoid 20 i.e. / 1 brizga  toksoid b. pertussis2,5 i.e. / 1 brizga  pertaktin3 i.e. / 1 brizga  fimbrij tipa 2 in 35 i.e. / 1 brizga; toksoid b. pertussis 2,5 i.e. / 1 brizga  pertaktin3 i.e. / 1 brizga  fimbrij tipa 2 in 35 i.e. / 1 brizga; pertaktin 3 i.e. / 1 brizga  fimbrij tipa 2 in 35 i.e. / 1 brizga; fimbrij tipa 2 in 3 5 i.e. / 1 brizga - cepivo proti oslovskemu kašlju s prečiščenimi antigeni in toksoidi

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sanofi pasteur - davični toksoid; hemaglutinin, filamentozni; tetanusni toksoid; toksoid b. pertussis; pertaktin; fimbrij tipa 2 in 3 - suspenzija za injiciranje v napolnjeni injekcijski brizgi - davični toksoid 2 i.e. / 1 brizga  hemaglutinin, filamentozni5 i.e. / 1 brizga  tetanusni toksoid20 i.e. / 1 brizga  toksoid b. pertussis2,5 i.e. / 1 brizga  pertaktin3 i.e. / 1 brizga  fimbrij tipa 2 in 35 i.e. / 1 brizga; hemaglutinin, filamentozni 5 i.e. / 1 brizga  tetanusni toksoid20 i.e. / 1 brizga  toksoid b. pertussis2,5 i.e. / 1 brizga  pertaktin3 i.e. / 1 brizga  fimbrij tipa 2 in 35 i.e. / 1 brizga; tetanusni toksoid 20 i.e. / 1 brizga  toksoid b. pertussis2,5 i.e. / 1 brizga  pertaktin3 i.e. / 1 brizga  fimbrij tipa 2 in 35 i.e. / 1 brizga; toksoid b. pertussis 2,5 i.e. / 1 brizga  pertaktin3 i.e. / 1 brizga  fimbrij tipa 2 in 35 i.e. / 1 brizga; pertaktin 3 i.e. / 1 brizga  fimbrij tipa 2 in 35 i.e. / 1 brizga; fimbrij tipa 2 in 3 5 i.e. / 1 brizga - cepivo proti oslovskemu kašlju s prečiščenimi antigeni in toksoidi

Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi pasteur s.a. - virus influence (inaktivirano, split) od naslednjih vrst:a/california/7/2009 (h1n1)pdm09 - kot seva a/california/7/2009, nymc x-179a)/hong kong/4801/2014 (h3n2) - kot sev (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - kot sev b/brisbane/60/2008, divji tip) - influenza, human; immunization - cepiva - preprečevanje gripe pri posameznikih, starih 60 let in več, zlasti pri tistih, ki imajo povečano tveganje za povezane zaplete. uporaba idflu mora temeljiti na uradnih priporočilih.

Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi pasteur europe - virus influence (inaktivirano, split) od naslednjih vrst:a/california/7/2009 (h1n1)pdm09 - kot seva a/california/7/2009, nymc x-179a)/hong kong/4801/2014 (h3n2) - kot sev (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - kot sev b/brisbane/60/2008, divji tip) - influenza, human; immunization - cepiva - preprečevanje gripe pri posameznikih, starih 60 let in več, zlasti pri tistih, ki imajo povečano tveganje za povezane zaplete. uporaba intanza mora temeljiti na uradnih priporočilih.

Evropska unija - slovenščina - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - površinski antigeni virusa influence (hemaglutinin in nevraminidaza) seva a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - cepiva - aktivna imunizacija proti podtipu h5n1 virusa influenca a. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Evropska unija - slovenščina - EMA (European Medicines Agency)

dynavax gmbh - površinski antigen hepatitisa b - hepatitis b - cepiva - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.

Evropska unija - slovenščina - EMA (European Medicines Agency)

seqirus gmbh - virus influence površinskih antigenov (haemagglutinin in neuraminidase), inaktivirano, naslednjih vrst:a/california/7/2009 (h1n1)pdm09 - kot sev(a/brisbane/10/2010, divji tip)a/Švica/9715293/2013 (h3n2) - kot sev(a/južna avstralija/55/2014, divji tip)b/phuket/3073/2013–kot sev(b/utah/9/2014, divji tip) - influenza, human; immunization - cepiva - preprečevanje influence za odrasle, zlasti pa pri tistih, ki vodijo povečano tveganje za zaplete, povezane. optaflu je treba uporabljati v skladu z uradnimi smernice.

Evropska unija - slovenščina - EMA (European Medicines Agency)

pfizer limited - pneumococcal oligosaccharide serotype 18c, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14 - pneumococcal infections; immunization - cepiva - aktivne imunizacije proti bolezni, ki povzroča streptococcus pneumoniae serotipe 4, 6b, iz 9v, 14, 18 c, 19f in 23f (vključno s sepso, meningitisom, pljučnica, bakteriemija in akutni otitis media) pri dojenčkih in otrocih od dveh mesecev do petih let starosti. uporaba prevenar je treba določiti na podlagi uradnih priporočil, ob upoštevanju vpliva invazivnih bolezni v različnih starostnih skupin, kot tudi variabilnost serotip epidemiologija v različnih geografskih področjih,.

Evropska unija - slovenščina - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamid - prostatične neoplazme - endokrini terapija - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.